The reduction in price target by a reputable analyst like Evercore ISI Group could lead to a negative short-term sentiment among investors, potentially causing a decrease in Rallybio's stock price. However, the maintenance of an Outperform rating suggests underlying confidence in the company's fundamentals, which may mitigate the impact.